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variables. CONCLUSIONS: Economic development is important support for health 
development, but economic growth will not naturally improve health especially for the 
government investment on health. Rational incentives for the government is essential 
for health development. 
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OBJECTIVES: The electronic databases (ED) has been increasing used for clinical 
research since it reﬂ ects a routine care with large and heterogeneous samples. 
However, few studies report on its validity for such purposes, especially the ED from 
community hospitals. This study aims to assess the validity of EDs based on data from 
patients with atrial ﬁ brillation (AF) receiving care from community hospitals in Phit-
sanulok. METHODS: The validity of ED was determined using out-patient medical 
records (OPMRs) as a gold standard. A total of 200 AF patients were randomly 
sampled from a pool of patients with ICD-10 of AF (I48) from two community 
hospitals during August 2007–July 2008. For each patient, data of a randomly selected 
visit from the ED was matched to data of the same visit from OPMRs, abstracted by 
a standardized data collection form. The ED was cross-validated with OPMRs based 
on patient’s comorbidities (risk factors for stroke) and bleeding events. All data were 
tabulated in a 2 × 2 format to calculate sensitivity, speciﬁ city and the Cohen’s Kappa 
adjusted for chance agreement. RESULTS: Out of 200 AF patients, 176 were docu-
mented as having diagnosis of AF in OPMRs (88%). The ED data on risk factors of 
stroke showed moderate to high sensitivity (range 66.67–100%) and high speciﬁ city 
(range 99.36–100%). These results suggest that the risk factors of stroke were coded 
accurately. Based on these data, the agreement between two databases was considered 
good to very good (calculated kappa range 0.7940–0.9680). The speciﬁ city based on 
major bleeding was 100%; however, sensitivity and the Cohen’s Kappa could not be 
determined because the major bleeding diagnosis was found neither in the EMRs nor 
the OPMRs. CONCLUSIONS: The electronic database of AF patients from com-
munity hospitals was valid and in good agreement with the OPMRs. 
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OBJECTIVES: To evaluate the collaborative program between pharmacists and nurses 
in improving the spontaneous reporting system (SRS) of ADR in Prapokklao hospital, 
and to explore the impact of the collaborative program on nurses’ knowledge about 
ADRs, capacity in detecting and reporting ADRs, and the level of satisfaction. 
METHODS: Several methods including experimental approach which categorized 
nurses into experimental and control groups, then compared knowledge before and 
after a training program and performance in detecting and reporting ADRs between 
both groups. Eight out of 52 nurses in the experimental group were intensively trained 
with knowledge about ADRs, and how to report ADRs in hospitalized patients. The 
rest (44 nurses) in the experimental group obtained knowledge from researchers and 
the training nurses. Nurses in both experimental and control groups were assessed 
about knowledge before and after the start of the program, performance in monitoring 
and reporting ADRs compared to pharmacists, and satisfaction using a self-adminis-
tered questionnaire. RESULTS: Eight nurses trained by the program and 44 nurses in 
the experimental group had a signiﬁ cant higher score of knowledge than before train-
ing. Differences in the pre and post-test scores between experimental and control 
groups were statistically signiﬁ cant at 0.05. Intensive ADR monitoring indicated that 
experimental wards had 3572 patients with 371 ADR problems, while control wards 
had 3467 patients with 266 problems. Nurses in the experimental groups could cor-
rectly report 174 ADR problems (46.9%), while 29 problems (10.9%) were reported 
by their counterparts. The difference in the capability to reporting ADR was at the 
signiﬁ cance level of 0.05. The level of probability and the difference in the proportion 
of ADR reported by the experimental group was fourfold to the control group. 
CONCLUSIONS: This collaborative program between pharmacists and nurses signiﬁ -
cantly improved performance and knowledge of nurse in SRS reporting system in 
Prapokklao hospital. 
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OBJECTIVES: Nowadays growing number of new health technologies entering 
market together with more aggressive therapies administered by physicians lead to 
increase in number and cost of care of related adverse effects (AE). We were interested 
in the impact of costs of AE related to medicines not recommended for public funding 
by the Consultative Council (CC) of Polish Heath Technology Assessment Agency 
(AHTAPol) on the ground of safety issues on the Polish National Health Fund’s 
budget. METHODS: Among decisions of CC published until the end of 2009, we 
distinguished those where safety issues were signiﬁ cant arguments for decline, and 
analyzed submissioned budget impact analyses (BIA) of those medicines in order to 
ﬁ nd the incremental costs of AE related to the treatment. Then, we compared those 
costs to the total incremental costs of public funding reported by manufacturers. 
RESULTS: Among 148 CC’s decisions analyzed, 70 were negative and in 22 safety 
issues were signiﬁ cant arguments against the positive recommendation (31% of all 
negative decisions). Out of 22 analyzed BIA’s only in two cases (10%) incremental 
costs of AE were explicitly stated, both medicines being used in oncology. In one case 
(4.5%), a reason for absence of those costs was stated. Stated incremental cost of AE 
of those two medicines was about 0.25 to 0.35 million USD in years 1 to 3 of public 
funding, which corresponds to about 2.5% of total incremental cost of those medicines 
and only 0.2% of total incremental costs of all 22 submissions (about 110 to 135 
million USD). CONCLUSIONS: In submissions rejected by CC where one of the 
main concerns were safety issues, manufacturers failed to explicitly show the impact 
of costs of adverse effects of their drugs on Polish National Health Fund’s 
budget. 
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OBJECTIVES: In recent years, there has been a steady increase in products for chronic 
rare diseases. The aim of this research is to assess the current pricing and reimburse-
ment framework for orphan and ultra-orphan drugs - identifying emerging trends, 
deﬁ ning the key components of health technology assessments, observing government 
and payer policies, and reviewing previous access decisions in relation to the Asia-
Paciﬁ c region. METHODS: Interviews were conducted with a variety of stakeholders 
(payers, academics, KOLs) to identify the key determinants inﬂ uencing the pricing and 
reimbursement and access strategies of orphan drugs in AP countries including Aus-
tralia, China, Japan, India, Singapore, South Korea. These were supported by in-depth 
secondary analyses from government websites, the WHO, reports and OECD statis-
tics. RESULTS: Decisions reviewed for a selection of drugs (e.g., Naglazyme, Glivec, 
Tracleer) across a number of therapeutic areas in the context of indicators including 
population size, price level, %GDP on health care (Singapore 3.4%, India 4.9%, 
China 4.5%, Australia 9.1%), number of specialists etc, inferred that there is signiﬁ -
cant variability in uptake. Orphan deﬁ nitions vary by country from 4/10,000 in Japan 
to 1.2/10,000 in Australia. Pricing, payment and regulation mechanisms also differ 
across countries including ﬁ nancial incentives, protocol assistance, fast-track proce-
dures and market exclusivity (Years: US = 7, EU = 10, Japan = 10, Australia = none). 
Nearly 100 orphan drugs have been approved over the past 12 years in Japan. In 
predominantly self-pay markets such as China and India, many orphan diseases 
remain untreated. Policy determinants include economic troubles impacting health-
care budgets, stakeholder attempts to rationalize investment, population demographic 
shifts, affordability, desire for consistency across and within markets and the require-
ment to contain rising health-care costs while respecting the philosophy of the health-
care system (egalitarian vs.ulitarian). CONCLUSIONS: Health system and payer 
attitudes toward health provision are evolving over time, impacting the type of 
approach taken to address orphan and ultra-orphan product access in the Asia-Paciﬁ c 
region. 
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OBJECTIVES: The research was aimed at understanding the complexities of pricing 
and reimbursement practices in UAE with analysis focussing on price mark-ups, 
affordability, stakeholder analysis and strategic recommendations for pharmaceutical 
companies to launch products in this market. METHODS: Interviews were conducted 
with Payers and KOLs to understand patient ﬂ ow, health-care issues and drug pricing 
in UAE. In addition in-depth secondary analysis was conducted. RESULTS: UAE with 
a population of 4.2 million has seen more than 700% growth from 1975–2006, 
contributed mostly by expatriate work force. This has signiﬁ cantly impacted on the 
management of health care in recent years. Medicines priced in the UAE are generally 
high because of the lack of pharmaceuticals manufacturing base and subsequent reli-
ance on imports. While individuals spend $52 in the gulf countries and $20 in other 
Arab countries on medicines, an individual in the UAE spends about $80 a year. There 
is a markup of up to 20% and 24% by the wholesalers and retail pharmacies, respec-
tively; which is relatively high in comparison to many other countries resulting in 
expensive drugs that become unaffordable. A lack of competition legislation and anti-
competitive practices means that pharmacies in the UAE are required to buy medicines 
solely through few agents who hold exclusive rights to importing and distributing 
products. Also there are differences among the UAE regions; e.g., HAAD is introduc-
ing additional controls through a differential co-payments and reference pricing when 
insufﬁ cient competition is observed. As part of market access policy development, the 
UAE MoH has started applying basic pharmaco-economic methodologies that consid-
ers the active ingredient’s strength, dosage, and therapeutic effect. CONCLUSIONS: 
The pricing and reimbursement policy in its current form is not-sustainable. New 
pricing models need to be considered in order to ensure a healthy population with 
good access to affordable medicines and health care in the UAE. 
